Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
All Genders
NCT06335160

Possible Efficacy and Safety of Mebendazole in Patients With Ulcerative Colitis Treated With Mesalamine

Led by Tanta University · Updated on 2026-02-06

46

Participants Needed

1

Research Sites

105 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

To evaluate the possible efficacy and safety of mebendazole in patients with ulcerative colitis treated with mesalamine

CONDITIONS

Official Title

Possible Efficacy and Safety of Mebendazole in Patients With Ulcerative Colitis Treated With Mesalamine

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Both male and female patients are included
  • Mild and moderate ulcerative colitis diagnosed and confirmed by endoscopy
  • Patient treated with 5-aminosalicylic acid (mesalamine)
Not Eligible

You will not qualify if you...

  • Patients with severe ulcerative colitis
  • Significant liver and kidney function abnormalities
  • Diabetic patients
  • Patients with colorectal cancer
  • Patients taking rectal or systemic steroids
  • Patients on immunosuppressants or biological therapies
  • Addiction to alcohol and/or drugs
  • Known allergy to the studied medications
  • History of complete or partial colectomy
  • Patients with congestive heart failure or other heart diseases (arrhythmia, ischemic heart disease including angina and myocardial infarction)
  • Patients with other inflammatory diseases and active infection
  • Patients with stressful conditions (COPD, morbid obesity)
  • Patients with liver disease
  • Patients with thrombocytopenia and neutropenia
  • Patients with any type of seizures
  • Patients with renal disease
  • Patients with coagulation disorders
  • Patients on metronidazole
  • Patients with hypersensitivity to mebendazole, albendazole, or benzimidazole
  • Patients using antioxidants
  • Pregnant and lactating females
  • Patients receiving metronidazole, warfarin, low dose aspirin, clopidogrel, enzyme inducers (phenytoin, carbamazepine) or inhibitors (valproate) to avoid drug interactions

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Tanta Unuversity

Tanta, Egypt, 34518

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here